Last updated on February 2018

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation


Brief description of study

This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .

Detailed Study Description

This is a multicenter study in adult patients with AF and ESRD who are on hemodialysis and who have stroke risk factors making them candidates for oral anticoagulation. Patients will be randomized to apixaban versus warfarin, and will be treated for up to 15 months.

Clinical Study Identifier: NCT02942407

Contact Investigators or Research Sites near you

Start Over

Eric Berrios

Genesis Clinical Research
Tampa, FL United States
  Connect »

Eric Berrios

Boise Kidney and Hypertension Institute
Meridian, ID United States
  Connect »

Eric Berrios

South Shore Nephrology
Plymouth, MA United States
  Connect »

Eric Berrios

Paragon Health Neprhology Centre
Kalamazoo, MI United States
  Connect »

Eric Berrios

Nephrology & Hypertension Associates
Tupelo, MS United States
  Connect »

Eric Berrios

Metro Hypertension & Kidney Center
Saint Louis, MO United States
  Connect »

Eric Berrios

Durham Nephrology Associates
Durham, NC United States
  Connect »

Eric Berrios

Northeast Clinical Research Ctr
Bethlehem, PA United States
  Connect »

Eric Berrios

Knoxville Kidney Center
Knoxville, TN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.